Phaseline

Companies › Jiangsu HengRui Medicine

Jiangsu HengRui Medicine: clinical trials, targets and expected readouts

50 active drug programs in 389 registered trials: 187 Phase 2, 84 Phase 3, 66 Phase 1, 52 Phase 4; Oncology, Other, Immunology, Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bupivacaine
Sodium channel protein type IV alpha subunit blocker
Ion channelsPhase 4Local Analgesia Via Infiltration; Local Analgesia Via Nerve Block; Robotic Lung Surgery; Low Back Pain …Nov 2026
SHR-A1811 for Injection
HER2-targeted antibody-drug conjugate
ERBB2Phase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane; Non-Small Cell Lung Cancer With HER2- Mutations; Ovarian Cancer; HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma …Nov 2026
SHR0302
JAK1 inhibitor
JAK1Phase 3Psoriatic Arthritis; Non-segmental VitiligoDec 2026
Lutetium (177Lu) Oxodotreotide Injection
Somatostatin receptor 2 (SSTR2)-targeting peptide radionuclide therapy
SSTR2Phase 3Advanced Gastroenteropancreatic Neuroendocrine TumorDec 2026
Pyrotinib
Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor
EGFR, ERBB2Phase 3Breast Cancer; Advanced Non-small Cell Lung Cancer; HER2-positive Breast Cancer; Metastatic Breast Cancer …Dec 2026
Fuzuloparib
PARP inhibitor
PARP1, PARP2Phase 3Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dec 2026
[14C]HRS-9190
Neuromuscular blocking agent
–Phase 3Neuromuscular Blockade; Healthy Adult MaleDec 2026
FH-006 for Injection–Phase 3Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy; Lung Cancer; Malignant Solid TumorFeb 2027
HRS-4642
KRAS G12D inhibitor
KRASPhase 3KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting; Advanced KRAS G12D Mutant Solid Tumors; Advanced Solid Tumors; Metastatic Pancreatic Carcinoma …Mar 2027
Rezvilutamide
Androgen Receptor antagonist
ARPhase 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer (Post Prostatectomy) …Mar 2027
Famitinib
Stem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1 inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor
KIT, FLT1, FLT3, PDGFRB, PDGFRAPhase 3Cervical Cancer; Triple-Negative Breast Cancer; TNBC - Triple-Negative Breast Cancer; Breast Neoplasm …May 2027
camrelizumab
Programmed cell death protein 1 antagonist
PDCD1Phase 3Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); Cervical Cancer …May 2027
HRS-4357 injection
PSMA-targeting therapy (likely anti-PSMA antibody-drug conjugate or radioligand)
–Phase 3PSMA-Positive Progressive Metastatic Castration-Resistant Prostate CancerDec 2027
SHR2554
HDAC inhibitor
–Phase 3Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy; Advanced Gastric Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer; Prostate CancerDec 2027
Hetrombopag Olamine
Thrombopoietin receptor agonist
MPLPhase 3Chemotherapy-Induced Thrombocytopenia; Patients With Chemotherapy-Induced Thrombocytopenia; ITP - Immune Thrombocytopenia; Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors …Dec 2028
SHR6390
CDK4/6 inhibitor
CDK4, CDK6Phase 3Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage,Female Breast CancerOct 2031
HRS-8427
Carbapenem antibiotic
–Phase 3Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP); Hospital-acquired Bacterial Pneumonia (HABP)–
Rivoceranib Mesylate
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 3Gastric Cancer; Hepatocellular Carcinoma; Hepatocellular Carcinoma (HCC); BCLC Stage C Hepatocellular Carcinoma …–
HR070803–Phase 2Colorectal CancerDec 2026
SHR-3167 Injection
GLP-1 receptor agonist
–Phase 2Type 2 Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Mellitus; Type 2 DiabetesDec 2026
SHR-A1904–Phase 2Advanced Gastric Cancer; Advanced Solid TumorsMar 2027
Shr-4640 (SHR4640)
Solute carrier family 22 member 12 inhibitor
SLC22A12Phase 2Primary Gout and HyperuricemiaJul 2027
HRS-4508 tablet
KRAS inhibitor
–Phase 2Solid Tumor; Lung Cancer; Advanced Solid TumorsSep 2027
Bevacizumab (BP102)
Vascular endothelial growth factor A inhibitor
VEGFAPhase 2Lung CancerNov 2027
RSS0343 tablets
CFTR potentiator
–Phase 2Adolescent AsthmaNov 2027
SHR-8068–Phase 2Lung CancerNov 2027
SHR-1701–Phase 2Advanced Gastric Cancer; Locally Advanced or Metastatic Non-small Cell Lung CancerDec 2027
Trastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Unresectable Locally Recurrent Breast CancerJun 2028
Adabelimumab
TWEAK/TNF superfamily ligand antagonist
TNFSF12Phase 2Locally Advanced or Metastatic Non-small Cell Lung CancerOct 2028
SHR0302Base gel–Phase 2Vitiligo–
HRS-2189–Phase 1Breast CancerDec 2026
HRS-5041 tablets–Phase 1Advanced Prostate Cancer; Prostate CancerDec 2026
HRS-6209
CDK4/6 inhibitor
–Phase 1Breast Cancer; Advanced Solid Tumors; Advanced Unresectable or Metastatic Breast CancerDec 2026
HRS-3738–Phase 1Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaDec 2026
HRS-1167–Phase 1Advanced Solid Tumors; Prostate Cancer; BRCA-Mutated Breast CarcinomaDec 2026
AG–Phase 1Advanced Solid Tumors; Borderline Resectable Pancreatic AdenocarcinomaMar 2027
SHR-4394–Phase 1Prostate CancerMar 2027
SHR-A1921–Phase 1Advanced Solid TumorsMar 2027
HRS-6768–Phase 1Advanced Solid TumorsApr 2027
HRS-9813
Unclear mechanism - requires further characterization
–Phase 1Advanced Unresectable or Metastatic Breast CancerDec 2027
HRS-6093
KRAS G12D inhibitor
KRASPhase 1Advanced KRAS G12D Mutant Solid TumorsMay 2028
HRS-7525–Phase 1Prostate CancerJun 2028
HRS-3005–Phase 1B-cell MalignancyOct 2028
HRS-2329
RAS inhibitor
–Phase 1Advanced Solid Tumors Harboring RAS Mutations or AmplificationsDec 2028
HRS-7172
RAS inhibitor
–Phase 1Advanced Solid Tumors Harboring RAS Mutations or Amplifications; Pancreatic CancerDec 2028
HRS-8364–Phase 1Solid TumorDec 2028
SHR-1049 Injection–Phase 1Advanced Solid TumorDec 2028
HRS-717
Unclear - code-named drug
–Phase 1Pancreatic CancerDec 2028
HRS-6213
PET imaging agent
–Phase 1Patients With Solid Tumors–
RSS0393 ointment–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03906617BupivacainePhase 4Robotic Lung SurgeryOtherApr 2022
NCT04704297BupivacainePhase 4Low Back PainOtherJul 2022
NCT05533463HRS-4642Phase 1Advanced KRAS G12D Mutant Solid TumorsOncologyJun 2024
NCT06806410BupivacainePhase 4Hand SurgeryOtherNov 2024
NCT05218889camrelizumabPhase 1Pancreatic CancerOncologyDec 2024
NCT06783764BupivacainePhase 4Post Operative AnalgesiaOtherFeb 2025
NCT05864014Hetrombopag OlaminePhase 3Chemotherapy-Induced ThrombocytopeniaHematologyMar 2025
NCT04680221BupivacainePhase 4Pain, PostoperativePsychiatryJun 2025
NCT05605639BupivacainePhase 4Chronic Neck PainOtherJul 2025
NCT04521153camrelizumabPhase 2Hepatocellular CarcinomaOncologyJul 2025
NCT04521153Rivoceranib MesylatePhase 2Hepatocellular CarcinomaOncologyJul 2025
NCT06569953BupivacainePhase 4Acute PainOtherAug 2025
NCT07178262BupivacainePhase 4Erector Spinae BlockOtherOct 2025
NCT06719180BupivacainePhase 4HysterectomyOtherOct 2025
NCT06753500BupivacainePhase 4Visceral PainPsychiatryNov 2025
NCT05224089BupivacainePhase 4Bowel DiseaseGastroenterologyNov 2025
NCT07065435PyrotinibPhase 2HER2 + Breast CancerOncologyDec 2025
NCT06385678HRS-4642Phase 1Advanced KRAS G12D Mutant Solid TumorsOncologyDec 2025
NCT06308393RSS0393 ointmentPhase 1HealthyImmunologyDec 2025
NCT05602636BupivacainePhase 4Forearm SurgeryOtherDec 2025
NCT04560127camrelizumabPhase 2Radioactive Iodine-refractory Differentiated Thyroid CancerOncologyDec 2025
NCT07070349HRS-6213Phase 1Patients With Solid TumorsOncologyJan 2026
NCT06165991BupivacainePhase 4Thoracic Paravertebral BlockOtherJan 2026
NCT07018453SHR-3167 InjectionPhase 2Type 2 Diabetes MellitusMetabolic and endocrineFeb 2026
NCT07051486SHR-A1811 for InjectionPhase 2Recurrent or Metastatic Cervical CancerOncologyFeb 2026
NCT06790862SHR0302Base gelPhase 2VitiligoImmunologyMar 2026
NCT06947330BupivacainePhase 3Modified Radical MastectomyOncologyMar 2026
NCT06947330BupivacainePhase 3Modified Radical MastectomyOncologyMar 2026
NCT07482709BupivacainePhase 1Post Operative Pain in Total Abdominal HystrectomyOtherMar 2026
NCT04342910camrelizumabPhase 3Gastric CancerOncologyApr 2026
NCT04342910Rivoceranib MesylatePhase 3Gastric CancerOncologyApr 2026
NCT06353529BupivacainePhase 4PituitaryMetabolic and endocrineApr 2026
NCT06349317camrelizumabPhase 2Hepatocellular CarcinomaOncologyMay 2026
NCT06122389SHR2554Phase 3Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyOncologyMay 2026
NCT05277168SHR-A1904Phase 1Advanced Solid TumorsOncologyMay 2026
NCT07494175[14C]HRS-9190Phase 1Healthy Adult MaleOtherMay 2026
NCT06817525camrelizumabPhase 2Triple-negative Breast CancerOncologyMay 2026
NCT06565910BupivacainePhase 4Femoral Neck FracturesOtherJun 2026
NCT07090928BupivacainePhase 4Arthroscopic SurgeryOtherJun 2026
NCT06714279BupivacainePhase 1Laparoscopic CholecystectomyOtherJun 2026
NCT07429448BupivacainePhase 1AppendectomyOtherJun 2026
NCT07409688BupivacainePhase 4Laparoscopic Cholecystectomy SurgeryOtherJun 2026
NCT05391971BupivacainePhase 4Post Traumatic Stress DisorderPsychiatryJun 2026
NCT05198609camrelizumabPhase 3Hepatocellular CarcinomaOncologyJul 2026
NCT07492693Hetrombopag OlaminePhase 2Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal TumorsOncologyJul 2026
NCT05320692camrelizumabPhase 3Hepatocellular CarcinomaOncologyJul 2026
NCT05320692Rivoceranib MesylatePhase 3Hepatocellular CarcinomaOncologyJul 2026
NCT07049835BupivacainePhase 1Inguinal HerniasGastroenterologyJul 2026
NCT04639180camrelizumabPhase 3Hepatocellular Carcinoma (HCC)OncologyJul 2026
NCT04639180Rivoceranib MesylatePhase 3Hepatocellular Carcinoma (HCC)OncologyJul 2026
NCT06639503BupivacainePhase 1Tibial Plateau FracturesOtherSep 2026
NCT06569056HRS-8427Phase 3Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)Infectious diseaseSep 2026
NCT07140640BupivacainePhase 4Cesarean Section ComplicationsOtherSep 2026
NCT07610148HRS-6209Phase 1Breast CancerOncologySep 2026
NCT05942001HRS-5041 tabletsPhase 1Advanced Prostate CancerOncologySep 2026
NCT06841731HRS-8427Phase 2Hospital-acquired Bacterial Pneumonia (HABP)Infectious diseaseSep 2026
NCT04979338BupivacainePhase 3Gender DysphoriaPsychiatrySep 2026
NCT06179004BupivacainePhase 3Distal Radius FracturesOtherOct 2026
NCT06711471camrelizumabPhase 2Gastric Cancer Adenocarcinoma MetastaticOncologyNov 2026
NCT05176002camrelizumabPhase 1Esophageal NeoplasmOncologyNov 2026

The 60 nearest readouts of 389 trials; the rest in the app.

Targets

ERBB2 (3) KRAS (2) PDCD1 (1) KDR (1) CDK4 (1) CDK6 (1) Ion channels (1) SSTR2 (1) MPL (1) KIT (1) FLT1 (1) FLT3 (1)

Companies with the same targets

Pfizer Roche Beijing Biotech Chia Tai Tianqing Pharmaceutical Group AstraZeneca Shenyang Sunshine Pharmaceutical Revolution Medicines Eli Lilly Sichuan Baili Pharmaceutical Shanghai Henlius Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.